New Zealand’s post-Ardern populist pivot angers Maori communityagilabet8 。

Published 21:47 IST, December 14th 2024 PM Modi, in Lok Sabha, blamed the 2012 power outage on the Congress-led UPA, highlighting his govt's 'One Nation, One Grid' and tackling global defamation. New Delhi: Prime Minister Narendra Modi on Saturday targeted the Congress -led UPA government for the largest power outage in the country in 2012 and said his government has worked towards 'One Nation, One Grid' and there is uninterrupted power supply in all parts of the country. Speaking in Lok Sabha during the discussion on the 'Glorious Journey of 75 Years of the Constitution of India', the Prime Minister said during the previous government, "we saw India being defamed in the world through headlines". "Several times, there was power in one part of the country but it was not supplied. So, there was pitch dark in the other part. During the previous government, we saw India being defamed before the world through headlines. We have seen those days. That is why, with the mantra of unity and upholding the sense of the Constitution, we fulfilled One Nation One Grid. That is why, today there is uninterrupted power supply in all corners of India," he said. The Prime Minister said that the success of Digital India has helped democratise technology. "Era has changed. We do not want haves and haves not a situation in the digital sector. That is why, we proudly say that the reason behind Digital India success story is that we tried to democratise technology," he said. The Prime Minister said the achievement of 75 years is not ordinary, it is extraordinary. "India's Constitution has brought us here by defeating the possibilities that were expressed for India at the time when the country attained independence. For this great achievement, besides the drafters of the Constitution, I would like to respectfully bow before the crores of people of India - they lived this new system...Citizens of India deserve all the praise," he said. "For all of us, for all citizens and all democracy-loving citizens across the world, this is a moment of great pride," he added. The two-day debate on 75 years of the Constitution started in Lok Sabha on Friday. (Except for the headline, this story has not been edited by Republic and is published from a syndicated feed.) Get Current Updates on India News , Entertainment News along with Latest News and Top Headlines from India and around the world. Updated 21:47 IST, December 14th 2024Shiffrin crashes out of Killington giant slalom won by Hector

Zayn Malik's comments to audience revealed as he pays tribute to Liam Payne on stageTEHRAN- The 2nd edition of the Palestine World Prize for Literature has received submissions from 26 countries, the secretary of the event has announced. A total of 345 book titles from 26 countries have been submitted to the prize’s secretariat in Tehran, Mohsen Parviz said, Mehr reported on Saturday. Regarding the selection process for the submitted works, Parviz explained that the award's scientific council approves judges who then review the submissions. "However, for the Palestine World Prize, we do not have a scientific council. Consequently, the Policy Council, responsible for major policies and scientific matters regarding the prize, serves in that capacity and appoints judges from various countries," he said. Parviz noted that judges for the second edition of the award were selected from Syria, Lebanon, Algeria, Palestine, Iraq, Yemen, Indonesia, India, and Iran. The initial review of submissions was conducted by two judges, and those that qualified for the next stage were subsequently discussed in a joint meeting with the head of the jury. He elaborated, "The process has been consistent across all subcategories; judges provided their reasoning for selecting works based on technique and content. The final decision was made collectively by the judges, the head of the jury, and the scientific secretary. Except for two categories with fewer submissions, five works were chosen for final evaluation and ranking." Parviz emphasized that the primary languages of submitted works were Arabic and Persian, thus leveraging distinguished Arabic-speaking scholars from various Arab countries for this task. “While the majority of submissions were in Arabic and Persian, there were also entries in English, Urdu, Malay, French, and Spanish.” Continuing, he stated, “The judging sessions for this award were conducted remotely using new technologies, setting a suitable precedent for future years, as it proved to be an efficient and successful method.” Six judging groups were formed in six different categories: plays, memoirs, short stories, children's literature, poetry, and novels. The highest volume of submissions came from the novel category, which received 106 entries, while the play category had the fewest, with only nine submissions, he noted. He further mentioned that final judges included professors from Iranian universities and language faculties. Additionally, the heads of Arab Writers Union in Syria and Algeria, Muhammad Al-Hourani and Youssef Shakra, assisted in the final judging process. Parviz affirmed that, despite the uncertainty surrounding which works will be selected, the mere focus on the theme of resistance and Palestine by writers and poets from various countries is of significant importance and a positive takeaway. He expressed hope that through effective media promotion, the selected works could be translated into other languages and serve as advocates for the accurately and artistically rendered narratives defending the Palestinian people. "Despite a smaller volume of submissions being reviewed over a longer period last time, the quality of works in this edition seems significantly higher,” he remarked. “Previous memoir submissions were also strong, but we are now witnessing a remarkable leap in the quality of novels and short stories. This advancement led to some hesitation in eliminating certain works to reach a final verdict, largely influenced by the recent events surrounding the Al-Aqsa Storm.” “The impact of Palestinian heroism on writers and poets will undoubtedly yield even higher quality works in the coming years," he mentioned. It has been decided that the closing ceremony of the second edition of the Palestine World Prize for Literature will be held on Monday in Baghdad, Iraq hosted by the Iraqi Prime Minister's Office, he concluded. The Palestine World Prize for Literature was established in 2018 in Iran by a collective decision of cultural organizations, writers' unions, and publications from various countries. This biennial award aims to recognize the best works published about Palestine. The first edition of this prize was held in 2022 in Beirut. SAB/Couple in mortgage hell, hit hard by Xmas

Amazon is investing an additional $4 billion in the artificial-intelligence startup Anthropic, as major technology companies rush to fund generative AI. This will bring Amazon’s .css-321ztr-OverridedLink.css-321ztr-OverridedLink:any-link{-webkit-text-decoration:none;text-decoration:none;color:rgba(54,119,168,1);border-bottom:1px solid;border-bottom-color:rgba(54,119,168,1);}.css-321ztr-OverridedLink.css-321ztr-OverridedLink:any-link.css-321ztr-OverridedLink.css-321ztr-OverridedLink:any-link svg{fill:rgba(54,119,168,1);}.css-321ztr-OverridedLink.css-321ztr-OverridedLink:any-link:hover{-webkit-text-decoration:none;text-decoration:none;color:rgba(47,112,157,1);border-bottom:1px solid;border-bottom-color:rgba(47,112,157,1);}.css-321ztr-OverridedLink.css-321ztr-OverridedLink:any-link:hover.css-321ztr-OverridedLink.css-321ztr-OverridedLink:any-link:hover svg{fill:rgba(47,112,157,1);} .css-1vykwuz-OverridedLink{display:inline;color:var(--color-interactiveLink010);-webkit-text-decoration:underline;text-decoration:underline;}@media screen and (prefers-reduced-motion: no-preference){.css-1vykwuz-OverridedLink{transition-property:color,fill;transition-duration:200ms,200ms;transition-timing-function:cubic-bezier(0, 0, .5, 1),cubic-bezier(0, 0, .5, 1);}}@media screen and (prefers-reduced-motion: reduce){.css-1vykwuz-OverridedLink{transition-property:color,fill;transition-duration:0ms;transition-timing-function:cubic-bezier(0, 0, .5, 1),cubic-bezier(0, 0, .5, 1);}}.css-1vykwuz-OverridedLink svg{fill:var(--color-interactiveLink010);}.css-1vykwuz-OverridedLink:hover:not(:disabled){color:var(--color-interactiveLink020);-webkit-text-decoration:underline;text-decoration:underline;}.css-1vykwuz-OverridedLink:hover:not(:disabled) svg{fill:var(--color-interactiveLink020);}.css-1vykwuz-OverridedLink:active:not(:disabled){color:var(--color-interactiveLink030);-webkit-text-decoration:underline;text-decoration:underline;}.css-1vykwuz-OverridedLink:active:not(:disabled) svg{fill:var(--color-interactiveLink030);}.css-1vykwuz-OverridedLink:visited:not(:disabled){color:var(--color-interactiveVisited010);-webkit-text-decoration:underline;text-decoration:underline;}.css-1vykwuz-OverridedLink:visited:not(:disabled) svg{fill:var(--color-interactiveVisited010);}.css-1vykwuz-OverridedLink:visited:hover:not(:disabled){color:var(--color-interactiveVisited010);-webkit-text-decoration:underline;text-decoration:underline;}.css-1vykwuz-OverridedLink:visited:hover:not(:disabled) svg{fill:var(--color-interactiveVisited010);}.css-1vykwuz-OverridedLink:focus-visible:not(:disabled){outline-color:var(--outlineColorDefault);outline-style:var(--outlineStyleDefault);outline-width:var(--outlineWidthDefault);outline-offset:var(--outlineOffsetDefault);}@media not all and (min-resolution: 0.001dpcm){@supports (-webkit-appearance: none) and (stroke-color: transparent){.css-1vykwuz-OverridedLink:focus-visible:not(:disabled){outline-style:var(--safariOutlineStyleDefault);}}}.css-1vykwuz-OverridedLink.css-1vykwuz-OverridedLink:any-link{-webkit-text-decoration:none;text-decoration:none;color:rgba(54,119,168,1);border-bottom:1px solid;border-bottom-color:rgba(54,119,168,1);}.css-1vykwuz-OverridedLink.css-1vykwuz-OverridedLink:any-link.css-1vykwuz-OverridedLink.css-1vykwuz-OverridedLink:any-link svg{fill:rgba(54,119,168,1);}.css-1vykwuz-OverridedLink.css-1vykwuz-OverridedLink:any-link:hover{-webkit-text-decoration:none;text-decoration:none;color:rgba(47,112,157,1);border-bottom:1px solid;border-bottom-color:rgba(47,112,157,1);}.css-1vykwuz-OverridedLink.css-1vykwuz-OverridedLink:any-link:hover.css-1vykwuz-OverridedLink.css-1vykwuz-OverridedLink:any-link:hover svg{fill:rgba(47,112,157,1);} AMZN total investment in Anthropic — which began last year — to $8 billion. Anthropic said the Seattle-based tech giant will maintain its position as a minority investor in the startup, founded by former leaders of the OpenAI (which is itself backed by Microsoft MSFT ).By PATRICK O’DONNELL The 74 The banking apprentices in Zurich, Switzerland look up from the loan applications on their laptops when trainer Burak Besler calls for their attention. “What do I actually need from the customer?,” Besler asks the second year apprentices, all 17 or 18 years old at the Chase Your Potential wirtschaftsschule — business school. “It’s really important that you know why these documents are being requested,” he tells them in German as part of their kreditprozess — credit process — class. “A few are simple and obvious, such as a standard ID card...And of course I also want to see how much he earns.” Created in 2003 by Switzerland’s five largest banks, the CYP banking school is unlike any in the United States. With 30 partnering banks, it’s a school where apprentices — many of them teenagers who would still be in high school in the U.S. — learn banking skills letting them work in any bank in the country. Now, the Indiana Bankers Association wants to create a version of CYP in Indianapolis as part of the state’s push to reinvent high schools and offer more meaningful work opportunities for students. The association plans to start a statewide banking apprenticeship by the fall of 2025 where high school juniors and seniors are paid to work and train at banks as often as three days a week, and attend high school the other two. Though common in Europe, Indiana’s new apprenticeship program would be one of the first large scale white collar apprentice programs in the U.S. Traditionally building trades apprenticeships have dominated here. Apprentices would rotate between bank departments for two years, sometimes directly working with customers and handling accounts, with the possibility of doing a third year while also attending college. Students will also receive extra training in banking skills at a new state Financial Services Academy based on CYP the association will host at its 75-seat training center it already uses for adults. Students would likely take classes there once a month, as Swiss apprentices do at CYP, either in person or live online if they are in other parts of the state. The Academy could later expand to include other financial industries such as insurance. The new banking apprenticeships, along with a similar effort with hospitals, will be the first steps in Indiana’s goal of better serving the 60 percent of high school students in the state who never attend college and earn any degree. Indiana Fifth Third Bank regional president Michael Ash visited CYP and member banks in Switzerland twice over the last two years as Indiana leaders crafted a plan unveiled this month to create thousands more apprenticeships. Those visits taught him the state could adapt and create opportunities for high school students that also would help banks. “It’ll give the student a lot more experience and...it will give the employer an opportunity to have an employee doing real work,” Ash told The 74. “I think it’s a win-win for the student and for the company.” Though some U.S. banks and insurance companies have hired apprentices, including J.P Morgan Chase and Zurich insurance, the new academy is likely the first in the U.S. where multiple banks jointly train apprentices of competitors, as well as of their own company. The American Bankers Association and several youth apprenticeship experts were unable to identify any other school like it. Cooperation and agreement between banks on the key skills they all want employees to have, then to consistently teach those to apprentices, is a key part of the European apprentice model. “It hasn’t been in an organized fashion (in the U.S.) before where the trade association is involved and also educating the students, which is a big piece of this,” said Amber Van Til, president of the Indiana association. “It’s going to give the banks the confidence that they (students) have also had the educational training that they need to be workforce ready.” The state legislature and department of education are reworking state diploma requirements to give students more course credit, and flexibility of class schedules, when students pursue work experience and training while still in school. At the same time, teams of leaders from the manufacturing, medical and financial service industries have visited Switzerland to learn from a country where about two thirds of students use apprenticeships to learn a career or launch into further study. Those trips have included stops to the CYP campus in Zurich, one of 12 in the country, that train about 6,000 apprentices a year combined. In classrooms carved out of a rehabilitated former foundry, apprentices take classes starting at age 16 or 17 that progress from the basics of retail banking — working with customers at the front desk — to how banks operate, how stock markets work, how to handle mortgage or construction loans and later investment banking by their third and final year. Altogether, CYP teaches apprentices 87 specific skills over the three years, such as this one: Simon Stadler, CEO of the 12-campus CYP system, said Swiss parents often prefer their children go to universities instead of doing apprenticeships, just like in the U.S. But the Swiss still regard apprenticeships highly and there are real practical advantages to learning a job through them. “Afterwards, you’re able to do it,” Stadler said. “You’re able to work from the first day in the bank, because you already know it. You have the experience and you also know how it works in real life.” CYP has shared its curriculum and overall banking apprenticeship plan with Indiana, which plans to adapt it slightly for the new academy. “We’re going to probably stick pretty close to the Swiss model,” said Van Til. “It’s very well developed...the tracks that they have, the rotations that they have, the education CYP is providing is pretty much in line.” Van Til said that though students will learn basic interaction with customers, they won’t be limited to just being traditional tellers, whose role she said has expanded over the years. They won’t be funneled into high—stakes investment banking either. “Just because you come in the bank and you want to be an investment banker doesn’t mean that’s where you’re going to end up,” she said. “We’re going to assess the student while they’re there, see where we think their skill set is and try and direct them to where we think would best be a fit.” How much demand Indiana high school students will have for banking apprenticeships isn’t clear. Students who have test—driven banking through internships at a bank branch located at Zionsville Community High School northwest of Indianapolis were intrigued. Mann Patel, now a sophomore majoring in finance at Indiana University, interned at the branch of Star Bank as a senior in 2023. That internship, just an hour a day for a semester, taught him enough about banking that he decided to continue pursuing the field, possibly focusing on wealth management. But committing to that path in 11th grade would have been too much for him, even if more hands—on work than what the internship offered would have been tempting. Akshara Amuhadin, a junior interning at that branch now, also hopes to find a career in finance. She said she likes hands-on learning and would likely try the new apprenticeship. “If you know for sure that this is the career that you want to go into, that’d be a really great way to get some real world experience about banking,” she said. Fifth Third’s Ash said he believes both banks and students will take advantage of apprenticeships that are long overdue. “When you see CYP and you see the students this seems so obvious,” he said. “You kind of kick yourself, like, why haven’t we done this sooner? Because it makes so much sense. But you know, we’re starting now, right? So we’ll get there.” This story was produced by The 74, a non-profit, independent news organization focused on education in America.Bengaluru techie suicide: Wife, in-laws seek anticipatory bail

None

Evaluating strategic options for iopofosine I 131 a late-stage clinical program with compelling Phase 2 data and a substantial market opportunity Focusing on advancing radiotherapeutic assets including alpha- and Auger-emitting radioconjugates into Phase 1 solid tumor studies FLORHAM PARK, N.J., Dec. 10, 2024 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage clinical biopharmaceutical company focused on the discovery, development and commercialization of drugs for the treatment of cancer, today announces a strategic update on its clinical development programs for its proprietary phospholipid ether drug conjugate platform that delivers a broad array of therapeutic modalities to target cancers. Due to recent communications with the U.S. Food and Drug Administration (FDA, or the Agency) regarding a confirmatory study to support accelerated approval and the regulatory submission for iopofosine I 131, the Company has decided to pursue strategic options for the further development and commercialization of this product candidate. The CLOVER-WaM study was conducted in accordance with earlier FDA communications from an end of Phase 2 meeting and from a meeting in early 2024, during which the Company was informed that positive results for major response rate (MRR) as the primary endpoint could be acceptable to support accelerated approval of iopofosine I 131 as a treatment for Waldenstrom’s macroglobulinemia (WM). Based upon a recent Type-C meeting with the FDA, the Company now believes that a submission seeking accelerated approval would need to be based on the MRR data from CLOVER-WaM and enrollment in a randomized, controlled confirmatory study that is designed to generate data on progression-free survival (PFS). “While iopofosine I 131’s positive WM data along with the high unmet medical need for these patients support further investment, we have determined that such a program may best be brought to market by a larger organization with greater resources. Importantly, partnering or divesting this program supports our commitment to providing this potentially life-saving drug to the patients who need it as quickly as possible,” stated James Caruso, president and CEO of Cellectar. “We believe iopofosine I 131 represents a compelling opportunity as it has shown strong efficacy and good tolerability based on our clinical studies. Moreover, the commercial work we conducted demonstrates iopofosine I 131’s substantial market opportunity based upon the product profile, which includes off-the-shelf global distribution, orphan pricing and existing unmet medical need.” Cellectar remains confident in the potential of its phospholipid ether drug conjugate platform and the targeted radiotherapies in its development pipeline. Iopofosine I 131’s clinical success validates the platform’s ability to target cancers and Cellectar will leverage its experience to focus on the development of its earlier clinical programs. Specifically, Cellectar will focus on those assets it believes have the highest therapeutic potential and opportunity for value creation. As highlighted by recent acquisitions and collaborations within the radiopharmaceutical sector, precision isotopes like alpha- and Auger-emitters have emerged as the leading therapeutics of interest. Consequently, the Company will now focus its resources on targeting solid tumors by advancing CLR 121225, its actinium-225 based program, and CLR 121125, its iodine-125 Auger-emitting program into the clinic. Cellectar expects to file Investigational New Drug applications in the first half of 2025 for both CLR-121225 and CLR-121125, which will allow the initiation of Phase 1 clinical studies in solid tumor cancers. Both programs have demonstrated robust in vivo activity, tolerability, excellent targeting and uptake in preclinical solid tumor models. The Company believes this approach will provide an expedited timeframe to achieve safety and proof-of-concept data in patients. The Company’s strategic reprioritization will impact all departments and result in an immediate reduction in headcount of approximately 60%, which should be complete by the end of the fourth quarter 2024. The Company anticipates that the implementation of the restructuring will extend its cash runway into the third quarter of 2025. “We are being methodical in our efforts to reorganize the company with the goal of conserving cash while maintaining the flexibility to execute immediate priorities and build for long-term growth and value creation. This reorganization is difficult but necessary for the future growth potential of Cellectar,” said Mr. Caruso. “I want to extend my deepest gratitude to our departing employees for their significant contributions to our work and their dedication to making a difference in the lives of patients.” About Cellectar Biosciences, Inc. Cellectar Biosciences is a late-stage clinical biopharmaceutical company focused on the discovery and development of proprietary drugs for the treatment of cancer, independently and through research and development collaborations. The company’s core objective is to leverage its proprietary Phospholipid Drug ConjugateTM (PDC) delivery platform to develop the next-generation of cancer cell-targeting treatments, delivering improved efficacy and better safety as a result of fewer off-target effects. The company’s product pipeline includes lead asset, iopofosine I 131, a small-molecule PDC designed to provide targeted delivery of iodine-131 (radioisotope), CLR 121225, an actinium-225 based program being targeted to several solid tumors with significant unmet need, such as pancreatic cancer, CLR 121125, an iodine-125 Auger-emitting program targeted in other solid tumors, such as triple negative breast, lung and colorectal, proprietary preclinical PDC chemotherapeutic programs and multiple partnered PDC assets. In addition, iopofosine I 131 is under evaluation in Phase 2b studies for relapsed or refractory multiple myeloma (MM) and central nervous system (CNS) lymphoma, alongside the CLOVER-2 Phase 1b study, targeting pediatric patients with high-grade gliomas, for which Cellectar is eligible to receive a Pediatric Review Voucher from the FDA upon approval. The FDA has also granted iopofosine I 131 Orphan Drug and Fast Track Designations for various cancer indications. New data from the CLOVER-WaM Phase 2 clinical trial were recently presented in an oral presentation at the 66th American Society of Hematology Annual Meeting and Exposition (ASH 2024). For more information, please visit www.cellectar.com or join the conversation by liking and following us on the company’s social media channels: Twitter, LinkedIn, and Facebook. Forward-Looking Statement Disclaimer This news release contains forward-looking statements. You can identify these statements by our use of words such as "may," "expect," "believe," "anticipate," "intend," "could," "estimate," "continue," "plans," or their negatives or cognates. These statements are only estimates and predictions and are subject to known and unknown risks and uncertainties that may cause actual future experience and results to differ materially from the statements made. These statements are based on our current beliefs and expectations as to such future outcomes. Drug discovery and development involve a high degree of risk. Factors that might cause such a material difference include, among others, uncertainties related to the ability to raise additional capital, uncertainties related to the disruptions at our sole source supplier of iopofosine, the ability to attract and retain partners for our technologies, the identification of lead compounds, the successful preclinical development thereof, patient enrollment and the completion of clinical studies, the FDA review process and other government regulation, our ability to obtain regulatory exclusivities, the availability of priority review vouchers, our ability to successfully develop and commercialize drug candidates, competition from other pharmaceutical companies, product pricing and third-party reimbursement. A complete description of risks and uncertainties related to our business is contained in our periodic reports filed with the Securities and Exchange Commission including our Form 10-K/A for the year ended December 31, 2023, and our Form 10-Q for the quarter ended September 30, 2024. These forward-looking statements are made only as of the date hereof, and we disclaim any obligation to update any such forward-looking statements. Contacts MEDIA: Christy Maginn Bliss Bio Health 703-297-7194 cmaginn@blissbiohealth.com INVESTORS: Anne Marie Fields Precision AQ 212-362-1200 annemarie.fields@precisionaq.com

Home entertainment holiday gift ideas at a discount